Treating patients with DM with abatacept, a fully human soluble recombinant fusion protein consisting of the co-inhibitory receptor CTLA-4 and Fc domain of human IgG1, reduced disease activity in nearly half of patients monitored. The gene discussed is CTLA4; the disease is dermatomyositis.